The cancer-specific lncRNA LISR customizes ribosomes to suppress antitumour immunity
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunityThe Journal of experimental medicine · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE222143_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA918368 and SRA study SRP415759. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6915562 MM099 treated with siControl rep1 MM099 treated with siCo…
- GSM6915563 MM099 treated with siControl rep2 MM099 treated with siCo…
- GSM6915564 MM099 treated with siControl rep3 MM099 treated with siCo…
- GSM6915565 MM099 treated with siLISR rep1 MM099 treated with siLI…
- GSM6915566 MM099 treated with siLISR rep2 MM099 treated with siLI…
- GSM6915567 MM099 treated with siLISR rep3 MM099 treated with siLI…
- GSM6915568 MM099 treated with siControl subunit fraction rep1 MM099 treated with siCo…
- GSM6915569 MM099 treated with siControl subunit fraction rep2 MM099 treated with siCo…
- GSM6915570 MM099 treated with siControl subunit fraction rep3 MM099 treated with siCo…
- GSM6915571 MM099 treated with siLISR subunit fraction rep1 MM099 treated with siLI…
- GSM6915572 MM099 treated with siLISR subunit fraction rep2 MM099 treated with siLI…
- GSM6915573 MM099 treated with siLISR subunit fraction rep3 MM099 treated with siLI…
- GSM6915574 MM099 treated with siControl early polysomes fraction rep1 MM099 treated with siCo…
- GSM6915575 MM099 treated with siControl early polysomes fraction rep2 MM099 treated with siCo…
- GSM6915576 MM099 treated with siControl early polysomes fraction rep3 MM099 treated with siCo…
- GSM6915577 MM099 treated with siLISR early polysomes fraction rep1 MM099 treated with siLI…
- GSM6915578 MM099 treated with siLISR early polysomes fraction rep2 MM099 treated with siLI…
- GSM6915579 MM099 treated with siLISR early polysomes fraction rep3 MM099 treated with siLI…
- GSM6915580 MM099 treated with siControl late polysomes fraction rep1 MM099 treated with siCo…
- GSM6915581 MM099 treated with siControl late polysomes fraction rep2 MM099 treated with siCo…
- GSM6915582 MM099 treated with siControl late polysomes fraction rep3 MM099 treated with siCo…
- GSM6915583 MM099 treated with siLISR late polysomes fraction rep1 MM099 treated with siLI…
- GSM6915584 MM099 treated with siLISR late polysomes fraction rep2 MM099 treated with siLI…
- GSM6915585 MM099 treated with siLISR late polysomes fraction rep3 MM099 treated with siLI…
- GSE268835 Denosumab Enhances antitumour Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells 9 samples shares antitumour, suppress, immunity
- GSE282897 PROCR diminishes the efficacy of radiation by impairing T cell-mediated antitumour immunity 4 samples shares antitumour, immunity
- GSE295518 synNotch CAR-Macrophages promote persistent antitumour activity through enhanced adaptive immunity [scRNA-Seq human] 2 samples shares antitumour, immunity
- GSE255775 Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype 319 samples shares cancer-specific
- GSE259422 Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype (plasma_cancer) 156 samples shares cancer-specific
- GSE260560 Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype (plasma_healthy) 70 samples shares cancer-specific
- GSE256268 Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype (tumor tissues) 42 samples shares cancer-specific
- GSE255774 Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype (cell mixture) 31 samples shares cancer-specific
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.